| (Values in U.S. Thousands) | Mar, 2016 | Dec, 2015 | Sep, 2015 | Jun, 2015 | Mar, 2015 |
| Sales | -9,999,000 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -9,999,000 | -5,960 | -5,350 | -6,380 | -5,170 |
| Net Income Growth | -167,668.46% | -11.40% | +16.14% | -23.40% | +58.34% |
Nephrogenex Inc (NRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
NephroGenex, Inc. is a pharmaceutical company focused on the development of therapeutics to treat kidney disease. It is developing a small molecule drug that acts as an inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. NephroGenex, Inc. is based in United States.